Literature DB >> 11190497

Cold ischemia in the absence of alloreactivity induces chronic transplant nephropathy through a process mediated by the platelet-activating factor.

I Herrero-Fresneda1, J Torras, N Lloberas, M Riera, J M Cruzado, E Condom, M Merlos, J Alsina, J M Grinyó.   

Abstract

BACKGROUND: Ischemia-reperfusion injury is considered a risk factor for the development of chronic transplant nephropathy (CTN) although the mechanisms that mediate its effects have not been completely established. We have previously shown that treatment with a platelet-activating factor (PAF) receptor antagonist (UR12670) protected kidneys from the progression to chronic nephropathy induced by warm ischemia. Here we examine the contribution of cold ischemia to the development of late functional and structural kidney changes in rats subjected to syngeneic renal transplantation and the role of PAF in this chronic nephropathy. SUBJECTS AND METHODS: Lewis rats were used as kidney donors and recipients, which were transplanted either immediately or after a cold ischemia period of 5 hr. Contralateral nephrectomy was performed on the seventh day after transplantation. Cyclosporine was administered for 15 days after transplantation. Groups were as follows: Sy, immediate transplantation; SyI, transplantation after 5 hr of cold ischemia; SyIUr, transplantation after 5 hr of cold ischemia plus UR12670 from the transplantation day to the end of the study, at 24 weeks. Serum creatinine, creatinine clearance, and proteinuria were determined every 4 weeks. Urinary

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11190497     DOI: 10.1097/00007890-200012150-00015

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

Review 1.  The role of platelet-activating factor in mesangial pathophysiology.

Authors:  Anna Reznichenko; Ron Korstanje
Journal:  Am J Pathol       Date:  2015-02-02       Impact factor: 4.307

2.  Do alloreactivity and prolonged cold ischemia cause different elementary lesions in chronic allograft nephropathy?

Authors:  Immaculada Herrero-Fresneda; Joan Torras; Josep M Cruzado; Enric Condom; August Vidal; Marta Riera; Nuria Lloberas; Jeroni Alsina; Josep M Grinyo
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

3.  Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model.

Authors:  Melania Kurdián; Inmaculada Herrero-Fresneda; Nuria Lloberas; Pepita Gimenez-Bonafe; Virginia Coria; María T Grande; José Boggia; Leonel Malacrida; Joan Torras; Miguel A Arévalo; Francisco González-Martínez; José M López-Novoa; Josep Grinyó; Oscar Noboa
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

4.  Mesenchymal stromal cells in renal ischemia/reperfusion injury.

Authors:  Dorottya K de Vries; Alexander F M Schaapherder; Marlies E J Reinders
Journal:  Front Immunol       Date:  2012-07-02       Impact factor: 7.561

5.  Ischemia-reperfusion injury accelerates human antibody-mediated transplant vasculopathy.

Authors:  Ryoichi Goto; Fadi Issa; Sebastiaan Heidt; David Taggart; Kathryn J Wood
Journal:  Transplantation       Date:  2013-07-27       Impact factor: 4.939

Review 6.  Review: Ischemia Reperfusion Injury-A Translational Perspective in Organ Transplantation.

Authors:  André Renaldo Fernández; Rodrigo Sánchez-Tarjuelo; Paolo Cravedi; Jordi Ochando; Marcos López-Hoyos
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.